Relief Therapeutics to merge with NeuroX to create AI-driven neurohealth company
Ella Day | July 29, 2025 | News story | Mergers and Acquisitions, Research and Development | AI, Corporate, MindMaze, Neurology, Relief Therapeutics, neurological conditions
Relief Therapeutics has announced that it will combine with NeuroX Group, the successor to digital neurotherapeutics company MindMaze. The transaction aims to create an artificial intelligence (AI)-powered therapeutics platform which integrates software-based neurorehabilitation with pharmacological treatments.
NeuroX recently acquired MindMaze’s assets and operations, inheriting a clinically-validated portfolio of digital therapies for neurological conditions such as stroke, Parkinson’s disease and dementia. The new entity plans to leverage AI, wearables and telehealth to deliver precision medicine across the care continuum.
Under the binding terms, NeuroX shareholders will receive newly issued shares in Relief based on agreed equity valuations of CHF1bn for NeuroX and CHF100m for Relief. Relief shareholders are expected to own approximately 9% of the combined entity after the transaction. The new company will continue to trade on the SIX Swiss Exchange, with closing anticipated in the final quarter of the year.
“This combination offers Relief shareholders the opportunity to participate in the growth of a scalable enterprise with the potential to become a multi-billion-dollar company,” said Raghuram Selvaraju, chair member of Relief.
Alexandre Capet, head of corporate development at NeuroX, added: “With increased visibility and a solid foundation in place, we believe this transaction comes at a pivotal inflection point in our journey.”
Ella Day
29/7/25
Related Content
Cori Clinical raises US$4m to expand AI platform for clinical trial design
Cori Clinical has raised US$4m in a seed funding round to expand its AI platform …
Agentic commercial: how AI creates dialogue with HCPs and patients to help medicines reach them faster
By Chris Moore Commercial engagement in biopharma used to centre largely on direct conversations between …
Liverpool launches £20m lab for infectious disease drug discovery
A new £20m high-security laboratory using robotics, artificial intelligence (AI) and human organoids to accelerate …
